Home LiteratureArticle Details
PMID: 22840745 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Advances in pharmacology (San Diego, Calif.) ·Vol. 64 ·2012-00-00 ·Pages 83-126

Silva DF, Selfridge JE, Lu J, E L, Cardoso SM, Swerdlow RH

Abstract

Mitochondria from persons with Alzheimer's disease (AD) differ from those of age-matched control subjects. Differences in mitochondrial morphology and function are well documented, and are not brain-limited. Some of these differences are present during all stages of AD, and are even seen in individuals who are without AD symptoms and signs but who have an increased risk of developing AD. This chapter considers the status of mitochondria in AD subjects, the potential basis for AD subject mitochondrial perturbations, and the implications of these perturbations. Data from multiple lines of investigation, including epidemiologic, biochemical, molecular, and cytoplasmic hybrid studies, are reviewed. The possibility that mitochondria could potentially constitute a reasonable AD therapeutic target is discussed, as are several potential mitochondrial medicine treatment strategies.

MeSH Terms
Alzheimer Disease/drug therapy,metabolism,pathology Animals DNA, Mitochondrial Humans Mitochondria/pathology Mitochondrial Diseases/drug therapy,metabolism,pathology Oxidation-Reduction Oxidative Stress
Chemicals
DNA, Mitochondrial
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Silva Diana F
Department of Neurology, University of Kansas School of Medicine, Kansas City, KS, USA.
Selfridge J Eva
Lu Jianghua
E Lezi
Cardoso Sandra M
Swerdlow Russell H
References (288)
288 references, click to expand
  1. Mitochondria as a target for neurotoxins and neuroprotective agents.
    Ann N Y Acad Sci. 2003 May;993:334-44; discussion 345-9 PMID: 12853325
  2. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease.
    Ann Neurol. 1994 Nov;36(5):747-51 PMID: 7979220
  3. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease.
    J Alzheimers Dis. 2011;26(1):59-68 PMID: 21593563
  4. Evidence of increased oxidative damage in subjects with mild cognitive impairment.
    Neurology. 2005 Apr 12;64(7):1152-6 PMID: 15824339
  5. Increased nuclear DNA oxidation in the brain in Alzheimer's disease.
    J Neurochem. 1998 Nov;71(5):2034-40 PMID: 9798928
  6. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment.
    Mitochondrion. 2006 Dec;6(6):323-30 PMID: 17123871
  7. Mitochondrial trafficking and the provision of energy and calcium buffering at excitatory synapses.
    Eur J Neurosci. 2010 Jul;32(2):231-40 PMID: 20946113
  8. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.
    Ann Neurol. 1991 Oct;30(4):572-80 PMID: 1789684
  9. Abnormalities of mitochondrial enzymes in Alzheimer disease.
    J Neural Transm (Vienna). 1998;105(8-9):855-70 PMID: 9869323
  10. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease.
    Neurobiol Dis. 2006 May;22(2):223-32 PMID: 16466929
  11. The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation.
    J Biol Chem. 2000 Feb 4;275(5):3173-8 PMID: 10652302
  12. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death.
    Am J Pathol. 1999 Nov;155(5):1459-66 PMID: 10550301
  13. Mitochondria: the common upstream driver of amyloid-β and tau pathology in Alzheimer's disease.
    Curr Alzheimer Res. 2011 Aug;8(5):563-72 PMID: 21244356
  14. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
    N Engl J Med. 1997 Apr 24;336(17):1216-22 PMID: 9110909
  15. In situ labeling of dying cortical neurons in normal aging and in Alzheimer's disease: correlations with senile plaques and disease progression.
    J Neuropathol Exp Neurol. 1996 Nov;55(11):1134-42 PMID: 8939196
  16. Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1.
    FASEB J. 2002 Dec;16(14):1879-86 PMID: 12468452
  17. Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease.
    Int J Biochem Cell Biol. 2009 Oct;41(10):1989-2004 PMID: 19703659
  18. Antioxidants and oxidative stress in exercise.
    Proc Soc Exp Biol Med. 1999 Dec;222(3):283-92 PMID: 10601887
  19. Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids.
    Nat Genet. 1997 Feb;15(2):212-5 PMID: 9020853
  20. Mitochondria in neuroplasticity and neurological disorders.
    Neuron. 2008 Dec 10;60(5):748-66 PMID: 19081372
  21. Differentiated Alzheimer's disease transmitochondrial cybrid cell lines exhibit reduced organelle movement.
    Antioxid Redox Signal. 2005 Sep-Oct;7(9-10):1101-9 PMID: 16115014
  22. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics.
    Biochim Biophys Acta. 2012 May;1822(5):639-49 PMID: 22037588
  23. Immunohistochemical evidence for apoptosis in Alzheimer's disease.
    Neuroreport. 1994 Dec 20;5(18):2529-33 PMID: 7696596
  24. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.
    Pharmacogenomics J. 2006 Jul-Aug;6(4):246-54 PMID: 16446752
  25. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease.
    Neurology. 2003 Dec 9;61(11):1498-502 PMID: 14663031
  26. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.
    Nature. 1991 Feb 21;349(6311):704-6 PMID: 1671712
  27. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling.
    Cell Signal. 2012 May;24(5):981-90 PMID: 22286106
  28. Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency.
    Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1768-73 PMID: 16446459
  29. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain.
    Hum Mol Genet. 2002 Jan 15;11(2):133-45 PMID: 11809722
  30. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
    J Pharmacol Exp Ther. 2007 Nov;323(2):438-49 PMID: 17720885
  31. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients.
    Am J Pathol. 2008 Aug;173(2):470-82 PMID: 18599615
  32. Effects of ageing and Alzheimer's disease on mitochondrial function of human platelets.
    Exp Gerontol. 2008 Jun;43(6):589-94 PMID: 18359596
  33. Polymorphic variation in cytochrome oxidase subunit genes.
    J Alzheimers Dis. 2010;21(1):141-54 PMID: 20413852
  34. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.
    Neurobiol Dis. 2009 May;34(2):381-8 PMID: 19264130
  35. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1.
    Free Radic Biol Med. 2002 Aug 15;33(4):562-71 PMID: 12160938
  36. Oxidative stress in Alzheimer disease: a possibility for prevention.
    Neuropharmacology. 2010 Sep-Oct;59(4-5):290-4 PMID: 20394761
  37. Caspase-mediated degeneration in Alzheimer's disease.
    Am J Pathol. 2004 Aug;165(2):353-5 PMID: 15277211
  38. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease.
    J Neurosci. 2008 Jul 2;28(27):6926-37 PMID: 18596167
  39. Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease.
    Biochim Biophys Acta. 2005 Jun 10;1740(3):472-80 PMID: 15949717
  40. Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase.
    J Alzheimers Dis. 2010;20 Suppl 2:S439-52 PMID: 20463399
  41. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha.
    Cell. 2006 Dec 15;127(6):1109-22 PMID: 17112576
  42. Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease.
    Antioxid Redox Signal. 2012 Jun 15;16(12):1434-55 PMID: 21902597
  43. Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease.
    Neurology. 2011 Mar 1;76(9):822-9 PMID: 21357834
  44. Lipid hydroperoxides induce apoptosis in T cells displaying a HIV-associated glutathione peroxidase deficiency.
    J Biol Chem. 1994 Jan 14;269(2):798-801 PMID: 8288627
  45. Is apoptosis key in Alzheimer's disease?
    Science. 1998 Aug 28;281(5381):1303-4 PMID: 9735049
  46. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients.
    Neurobiol Aging. 2005 May;26(5):567-73 PMID: 15708428
  47. Human coenzyme Q10 deficiency.
    Neurochem Res. 2007 Apr-May;32(4-5):723-7 PMID: 17094036
  48. Mitochondrial medicine for aging and neurodegenerative diseases.
    Neuromolecular Med. 2008;10(4):291-315 PMID: 18566920
  49. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism.
    Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19067-72 PMID: 18003925
  50. Alzheimer's disease: new approaches to drug discovery.
    Curr Opin Chem Biol. 2009 Jun;13(3):303-8 PMID: 19467915
  51. Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.
    Hum Mol Genet. 2012 Jan 15;21(2):406-20 PMID: 21997870
  52. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study.
    J Neuropathol Exp Neurol. 2005 Feb;64(2):113-22 PMID: 15751225
  53. Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer's disease and dementia with Lewy bodies.
    Acta Neuropathol. 2001 Jun;101(6):616-24 PMID: 11515791
  54. Mitochondrial decay in aging.
    Biochim Biophys Acta. 1995 May 24;1271(1):165-70 PMID: 7599204
  55. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons.
    Biochim Biophys Acta. 2011 Apr;1812(4):507-13 PMID: 21241801
  56. Microtubule stabilizing drugs for the treatment of Alzheimer's disease.
    Neurobiol Aging. 1994;15 Suppl 2:S87-9 PMID: 7700471
  57. Caspase-3 cleaved spectrin colocalizes with neurofilament-immunoreactive neurons in Alzheimer's disease.
    Neuroscience. 2006 Aug 25;141(2):863-874 PMID: 16750894
  58. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.
    Nutr Metab (Lond). 2009 Aug 10;6:31 PMID: 19664276
  59. Autophagy in the pathogenesis of disease.
    Cell. 2008 Jan 11;132(1):27-42 PMID: 18191218
  60. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease.
    Brain Res. 2007 May 7;1148:243-8 PMID: 17395167
  61. Biochemical effects of SIRT1 activators.
    Biochim Biophys Acta. 2010 Aug;1804(8):1626-34 PMID: 19897059
  62. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor.
    Nature. 1987 Feb 19-25;325(6106):733-6 PMID: 2881207
  63. Development of mitochondrial gene replacement therapy.
    J Bioenerg Biomembr. 2004 Aug;36(4):387-93 PMID: 15377877
  64. Diet, energy metabolism and mitochondrial biogenesis.
    Curr Opin Clin Nutr Metab Care. 2007 Nov;10(6):679-87 PMID: 18089947
  65. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde".
    Clin Anat. 1995;8(6):429-31 PMID: 8713166
  66. Autophagy: many paths to the same end.
    Mol Cell Biochem. 2004 Aug;263(1-2):55-72 PMID: 15524167
  67. Activation of caspase-6 in aging and mild cognitive impairment.
    Am J Pathol. 2007 Apr;170(4):1200-9 PMID: 17392160
  68. Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: insights into memory loss in MCI.
    J Alzheimers Dis. 2011;23(2):257-69 PMID: 20930294
  69. NAP prevents acute cerebral oxidative stress and protects against long-term brain injury and cognitive impairment in a model of neonatal hypoxia-ischemia.
    Neurobiol Dis. 2011 Oct;44(1):152-9 PMID: 21757007
  70. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication.
    Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10726-31 PMID: 15247418
  71. Sirtuins in aging and disease.
    Cold Spring Harb Symp Quant Biol. 2007;72:483-8 PMID: 18419308
  72. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease.
    J Neurochem. 2012 Feb;120(3):419-29 PMID: 22077634
  73. Methylene blue improves brain oxidative metabolism and memory retention in rats.
    Pharmacol Biochem Behav. 2004 Jan;77(1):175-81 PMID: 14724055
  74. Oxidative stress in the progression of Alzheimer disease in the frontal cortex.
    J Neuropathol Exp Neurol. 2010 Feb;69(2):155-67 PMID: 20084018
  75. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia.
    J Alzheimers Dis. 2010;20 Suppl 2:S293-310 PMID: 20463402
  76. Mitochondrial control of autophagic lysosomal pathway in Alzheimer's disease.
    Exp Neurol. 2010 Jun;223(2):294-8 PMID: 19559703
  77. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.
    J Alzheimers Dis. 2004 Dec;6(6 Suppl):S37-41 PMID: 15665412
  78. Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons.
    J Neurochem. 2003 Jan;84(2):347-62 PMID: 12558997
  79. Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's.
    Biol Psychiatry. 2010 Nov 15;68(10):913-21 PMID: 20817151
  80. Oxidative damage to DNA in lymphocytes from AD patients.
    Neurology. 1998 Oct;51(4):1014-7 PMID: 9781522
  81. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment.
    Neurosci Lett. 2006 Apr 24;397(3):170-3 PMID: 16413966
  82. Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia.
    Arch Gerontol Geriatr. 2001 Jun;32(3):275-82 PMID: 11395173
  83. Mitochondrial abnormalities in Alzheimer's disease.
    J Neurosci. 2001 May 1;21(9):3017-23 PMID: 11312286
  84. The Alzheimer's disease mitochondrial cascade hypothesis.
    J Alzheimers Dis. 2010;20 Suppl 2:S265-79 PMID: 20442494
  85. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
    Science. 2002 Jul 19;297(5580):353-6 PMID: 12130773
  86. Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases.
    Curr Pharm Des. 2011;17(31):3356-73 PMID: 21902672
  87. The mitochondrial protein hFis1 regulates mitochondrial fission in mammalian cells through an interaction with the dynamin-like protein DLP1.
    Mol Cell Biol. 2003 Aug;23(15):5409-20 PMID: 12861026
  88. Mitochondrial fusion protects against neurodegeneration in the cerebellum.
    Cell. 2007 Aug 10;130(3):548-62 PMID: 17693261
  89. The effect of aging and caloric restriction on mitochondrial protein density and oxygen consumption.
    Exp Gerontol. 2004 Mar;39(3):289-95 PMID: 15036388
  90. 2011 Alzheimer's disease facts and figures.
    Alzheimers Dement. 2011 Mar;7(2):208-44 PMID: 21414557
  91. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type.
    Science. 1990 Jun 1;248(4959):1124-6 PMID: 2111584
  92. Inherent abnormalities in oxidative metabolism in Alzheimer's disease: interaction with vascular abnormalities.
    Ann N Y Acad Sci. 1997 Sep 26;826:382-5 PMID: 9329708
  93. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell.
    Curr Alzheimer Res. 2007 Dec;4(5):507-9 PMID: 18220512
  94. Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease.
    Neurology. 2010 Jan 12;74(2):113-20 PMID: 20065246
  95. Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease.
    J Neuropathol Exp Neurol. 1998 Nov;57(11):1041-52 PMID: 9825941
  96. Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies.
    Pharmaceuticals (Basel). 2009 Dec 3;2(3):150-167 PMID: 21814473
  97. Inactivation and reactivation of the mitochondrial α-ketoglutarate dehydrogenase complex.
    J Biol Chem. 2011 May 20;286(20):17640-8 PMID: 21454586
  98. Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease.
    J Alzheimers Dis. 2008 Sep;15(1):117-28 PMID: 18780972
  99. Association of parental dementia with cognitive and brain MRI measures in middle-aged adults.
    Neurology. 2009 Dec 15;73(24):2071-8 PMID: 20007524
  100. The frequency of point mutations in mitochondrial DNA is elevated in the Alzheimer's brain.
    Biochem Biophys Res Commun. 2000 Jun 24;273(1):203-8 PMID: 10873587
  101. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.
    Arch Neurol. 2002 Jun;59(6):972-6 PMID: 12056933
  102. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.
    Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10540-3 PMID: 1683703
  103. Acetylated microtubules are required for fusion of autophagosomes with lysosomes.
    BMC Cell Biol. 2010 Nov 22;11:89 PMID: 21092184
  104. A beta oligomers - a decade of discovery.
    J Neurochem. 2007 Jun;101(5):1172-84 PMID: 17286590
  105. Oxidative stress as a mediator of apoptosis.
    Immunol Today. 1994 Jan;15(1):7-10 PMID: 8136014
  106. Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization.
    Neurology. 1995 Mar;45(3 Pt 1):482-6 PMID: 7898701
  107. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
    Schizophr Res. 2012 Apr;136(1-3):25-31 PMID: 22169248
  108. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage.
    Neuromolecular Med. 2004;5(2):147-62 PMID: 15075441
  109. Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death.
    J Alzheimers Dis. 2010;21(2):389-402 PMID: 20555134
  110. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.
    JAMA. 2007 Feb 28;297(8):842-57 PMID: 17327526
  111. Cytochrome oxidase deficiency in Alzheimer's disease.
    Neurology. 1990 Aug;40(8):1302-3 PMID: 2166249
  112. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation.
    Am J Pathol. 2003 May;162(5):1623-7 PMID: 12707046
  113. The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, in different brain regions in Alzheimer's disease.
    Neurochem Res. 1999 Jun;24(6):767-74 PMID: 10447460
  114. Increased immunoreactivity of brain spectrin in Alzheimer disease: a marker for synapse loss?
    Brain Res. 1990 Oct 29;531(1-2):36-44 PMID: 2289136
  115. Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for beta-amyloid peptide over-production and localization in Alzheimer's disease.
    Int J Biochem Cell Biol. 2004 Dec;36(12):2531-40 PMID: 15325590
  116. Mitochondria in Alzheimer's disease.
    Int Rev Neurobiol. 2002;53:341-85 PMID: 12512346
  117. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71.
    J Neurochem. 2002 Sep;82(6):1524-32 PMID: 12354300
  118. Oxidative stress level in circulating neutrophils is linked to neurodegenerative diseases.
    J Clin Immunol. 2004 Nov;24(6):683-92 PMID: 15622453
  119. Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer's disease.
    Neurobiol Aging. 2002 Jan-Feb;23(1):47-53 PMID: 11755018
  120. Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease.
    J Cell Biol. 2005 Oct 10;171(1):87-98 PMID: 16203860
  121. Oxidative stress in Alzheimer's disease.
    Biochim Biophys Acta. 2000 Jul 26;1502(1):139-44 PMID: 10899439
  122. Peripheral biomarkers of oxidative damage in Alzheimer's disease: the road ahead.
    Neurobiol Aging. 2005 May;26(5):581-3 PMID: 15708431
  123. Emerging therapeutic approaches to mitochondrial diseases.
    Dev Disabil Res Rev. 2010;16(2):219-29 PMID: 20818736
  124. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease.
    J Neurosci. 2009 Jul 15;29(28):9090-103 PMID: 19605646
  125. Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction.
    Genes Dev. 2006 Nov 1;20(21):2913-21 PMID: 17079682
  126. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage.
    Hum Mol Genet. 2011 Jul 1;20(13):2495-509 PMID: 21459773
  127. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons.
    J Alzheimers Dis. 2010;20 Suppl 2:S609-31 PMID: 20463406
  128. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease.
    J Neurochem. 1997 May;68(5):2092-7 PMID: 9109537
  129. Oxidatively modified RNA in mild cognitive impairment.
    Neurobiol Dis. 2008 Feb;29(2):169-75 PMID: 17920285
  130. Evidence for apoptotic cell death in Alzheimer's disease.
    Exp Neurol. 1995 Jun;133(2):225-30 PMID: 7544290
  131. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.
    JAMA. 1989 Nov 10;262(18):2551-6 PMID: 2810583
  132. Signal transduction cascades associated with oxidative stress in Alzheimer's disease.
    J Alzheimers Dis. 2007 May;11(2):143-52 PMID: 17522439
  133. Oxidative state in platelets and erythrocytes in aging and Alzheimer's disease.
    Neurobiol Aging. 2005 Jun;26(6):857-64 PMID: 15718044
  134. Mitochondria: dynamic organelles in disease, aging, and development.
    Cell. 2006 Jun 30;125(7):1241-52 PMID: 16814712
  135. Mitochondrial approaches for neuroprotection.
    Ann N Y Acad Sci. 2008 Dec;1147:395-412 PMID: 19076459
  136. Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias.
    J Neurochem. 1990 Nov;55(5):1624-30 PMID: 2213015
  137. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.
    Nat Med. 2011 Nov 20;17(12):1652-6 PMID: 22101764
  138. Caspases as therapeutic targets in Alzheimer's disease: is it time to "cut" to the chase?
    Int J Clin Exp Pathol. 2009;2(2):108-18 PMID: 19079646
  139. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain.
    Neurobiol Dis. 2002 Nov;11(2):341-54 PMID: 12505426
  140. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia.
    Arch Neurol. 2009 Mar;66(3):352-61 PMID: 19273754
  141. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease.
    J Neurochem. 1997 Jun;68(6):2451-7 PMID: 9166739
  142. Antioxidants in central nervous system diseases: preclinical promise and translational challenges.
    J Alzheimers Dis. 2008 Nov;15(3):473-93 PMID: 18997301
  143. Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease.
    J Alzheimers Dis. 2011;27(3):483-90 PMID: 21841246
  144. Alzheimer's disease: the two-hit hypothesis.
    Lancet Neurol. 2004 Apr;3(4):219-26 PMID: 15039034
  145. The key role of mitochondria in Alzheimer's disease.
    J Alzheimers Dis. 2006 Jul;9(2):101-10 PMID: 16873957
  146. Mitochondrial reactive oxygen species in mice lacking superoxide dismutase 2: attenuation via antioxidant treatment.
    J Biol Chem. 2006 Feb 10;281(6):3354-9 PMID: 16326710
  147. Abnormality of the alpha-ketoglutarate dehydrogenase complex in fibroblasts from familial Alzheimer's disease.
    Ann Neurol. 1994 Mar;35(3):312-8 PMID: 8122883
  148. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease.
    Neurology. 2009 Feb 10;72(6):513-20 PMID: 19005175
  149. The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells.
    Mol Pharmacol. 2007 Jun;71(6):1695-702 PMID: 17387142
  150. Mitochondrial superoxide contributes to blood flow and axonal transport deficits in the Tg2576 mouse model of Alzheimer's disease.
    PLoS One. 2010 May 10;5(5):e10561 PMID: 20479943
  151. Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease.
    Antioxid Redox Signal. 2010 Mar;12(3):327-36 PMID: 19686046
  152. Activation of caspase-8 in the Alzheimer's disease brain.
    Neurobiol Dis. 2001 Dec;8(6):1006-16 PMID: 11741396
  153. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease.
    Lab Invest. 2000 Aug;80(8):1323-35 PMID: 10950123
  154. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.
    Biochem Biophys Res Commun. 1984 May 16;120(3):885-90 PMID: 6375662
  155. Functions and dysfunctions of mitochondrial dynamics.
    Nat Rev Mol Cell Biol. 2007 Nov;8(11):870-9 PMID: 17928812
  156. Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes.
    Hum Genomics. 2010 Feb;4(3):170-93 PMID: 20368139
  157. Mitochondrial aging and dysfunction in Alzheimer's disease.
    Prog Neuropsychopharmacol Biol Psychiatry. 2005 Mar;29(3):407-10 PMID: 15795049
  158. Correlations of disability and biologic alterations in Alzheimer brain and test of significance by a therapeutic trial in humans.
    J Alzheimers Dis. 2006 Jul;9(2):207-18 PMID: 16873967
  159. Quantitative assessment of DNA fragmentation and beta-amyloid deposition in insular cortex and midfrontal gyrus from patients with Alzheimer's disease.
    Life Sci. 2003 Aug 22;73(14):1795-803 PMID: 12888118
  160. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease.
    J Cell Biol. 1998 Nov 2;143(3):777-94 PMID: 9813097
  161. Candidate gene for the chromosome 1 familial Alzheimer's disease locus.
    Science. 1995 Aug 18;269(5226):973-7 PMID: 7638622
  162. Peripheral antioxidant markers in mild cognitive impairment and its progression to dementia.
    J Alzheimers Dis. 2010;21(4):1179-83 PMID: 21504127
  163. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease.
    J Neurosci. 2011 Nov 2;31(44):15703-15 PMID: 22049413
  164. The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis?
    Trends Neurosci. 2008 May;31(5):251-6 PMID: 18403030
  165. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress.
    J Cell Biol. 2002 Mar 18;156(6):1051-63 PMID: 11901170
  166. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria.
    Biochem J. 1980 Nov 1;191(2):421-7 PMID: 6263247
  167. Amyloid-β-induced mitochondrial dysfunction impairs the autophagic lysosomal pathway in a tubulin dependent pathway.
    J Alzheimers Dis. 2011;26(3):565-81 PMID: 21694451
  168. Autophagy, amyloidogenesis and Alzheimer disease.
    J Cell Sci. 2007 Dec 1;120(Pt 23):4081-91 PMID: 18032783
  169. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease.
    Am J Pathol. 2004 Aug;165(2):523-31 PMID: 15277226
  170. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment.
    Free Radic Res. 2008 Feb;42(2):162-70 PMID: 18297609
  171. Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology.
    Acta Neuropathol. 1999 Apr;97(4):346-54 PMID: 10208273
  172. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways.
    FASEB J. 2008 Mar;22(3):703-12 PMID: 17928358
  173. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases.
    Nature. 2006 Oct 19;443(7113):787-95 PMID: 17051205
  174. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease.
    Science. 1989 Jul 28;245(4916):417-20 PMID: 2474201
  175. Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice.
    Nat Cell Biol. 2009 Aug;11(8):958-66 PMID: 19578372
  176. Dependence of H2O2 formation by rat heart mitochondria on substrate availability and donor age.
    J Bioenerg Biomembr. 1997 Feb;29(1):89-95 PMID: 9067806
  177. Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment.
    J Bioenerg Biomembr. 2009 Oct;41(5):441-6 PMID: 19777328
  178. Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA).
    J Mol Neurosci. 2001 Feb;16(1):41-8 PMID: 11345519
  179. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease.
    J Neurosci. 1999 Mar 15;19(6):1959-64 PMID: 10066249
  180. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.
    Proc Natl Acad Sci U S A. 1986 Jul;83(13):4913-7 PMID: 3088567
  181. Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury.
    J Neurochem. 2004 Aug;90(3):758-64 PMID: 15255955
  182. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease.
    Brain Res. 1998 Jan 12;780(2):260-9 PMID: 9507158
  183. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism.
    J Neurochem. 2009 Nov;111(4):915-33 PMID: 19780894
  184. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication.
    J Biol Chem. 2004 Jul 2;279(27):28531-8 PMID: 15123709
  185. Classification of European mtDNAs from an analysis of three European populations.
    Genetics. 1996 Dec;144(4):1835-50 PMID: 8978068
  186. Decreased brain protein levels of cytochrome oxidase subunits in Alzheimer's disease and in hereditary spinocerebellar ataxia disorders: a nonspecific change?
    J Neurochem. 1999 Feb;72(2):700-7 PMID: 9930743
  187. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease.
    Biochim Biophys Acta. 2012 Feb;1822(2):101-10 PMID: 22080977
  188. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42.
    J Neurochem. 2001 Jul;78(2):413-6 PMID: 11461977
  189. Role of by-products of lipid oxidation in Alzheimer's disease brain: a focus on acrolein.
    J Alzheimers Dis. 2010;21(3):741-56 PMID: 20634576
  190. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury.
    Science. 2009 Apr 3;324(5923):102-5 PMID: 19342591
  191. The development of mitochondrial medicine.
    Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8731-8 PMID: 8090715
  192. The ketogenic diet increases mitochondrial uncoupling protein levels and activity.
    Ann Neurol. 2004 Apr;55(4):576-80 PMID: 15048898
  193. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.
    Lancet. 2008 Jul 19;372(9634):207-15 PMID: 18640457
  194. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.
    Science. 1996 Oct 4;274(5284):99-102 PMID: 8810256
  195. Adaptations of skeletal muscle to endurance exercise and their metabolic consequences.
    J Appl Physiol Respir Environ Exerc Physiol. 1984 Apr;56(4):831-8 PMID: 6373687
  196. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins.
    Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19318-23 PMID: 19050078
  197. In situ immunodetection of neuronal caspase-3 activation in Alzheimer disease.
    J Neuropathol Exp Neurol. 1999 Sep;58(9):1020-6 PMID: 10499444
  198. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses.
    Cell. 2004 Dec 17;119(6):873-87 PMID: 15607982
  199. Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD.
    Neurology. 2001 Jul 24;57(2):260-4 PMID: 11468310
  200. Increased spectrin proteolysis in fibroblasts from aged and Alzheimer donors.
    Neurosci Lett. 1991 Jan 2;121(1-2):239-43 PMID: 2020380
  201. Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases.
    Biochim Biophys Acta. 2010 Jan;1802(1):122-34 PMID: 19715758
  202. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality.
    Ann Intern Med. 2005 Jan 4;142(1):37-46 PMID: 15537682
  203. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications.
    Ann Neurol. 2005 May;57(5):695-703 PMID: 15852400
  204. Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model.
    Neurobiol Dis. 2011 Dec;44(3):327-39 PMID: 21827858
  205. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies.
    J Neurosci Res. 2007 Nov 15;85(15):3416-28 PMID: 17243174
  206. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease.
    Am J Pathol. 2001 Jan;158(1):189-98 PMID: 11141492
  207. Mitochondrial fusion/fission, transport and autophagy in Parkinson's disease: when mitochondria get nasty.
    Parkinsons Dis. 2011 Feb 20;2011:767230 PMID: 21403911
  208. Mitochondria, oxidants, and aging.
    Cell. 2005 Feb 25;120(4):483-95 PMID: 15734681
  209. Abnormal brain spectrin immunoreactivity in sprouting neurons in Alzheimer disease.
    Neurosci Lett. 1991 Aug 5;129(1):1-5 PMID: 1922957
  210. Mild cognitive impairment represents early-stage Alzheimer disease.
    Arch Neurol. 2001 Mar;58(3):397-405 PMID: 11255443
  211. Addressing Alzheimer's disease tangles: from NAP to AL-108.
    Curr Alzheimer Res. 2009 Oct;6(5):455-60 PMID: 19874271
  212. Impaired axonal transport of cortical neurons in Alzheimer's disease is associated with neuropathological changes.
    Brain Res. 2002 Sep 6;948(1-2):138-44 PMID: 12383965
  213. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease.
    Neurobiol Aging. 1998 Jan-Feb;19(1):33-6 PMID: 9562500
  214. Cytochrome c oxidase is decreased in Alzheimer's disease platelets.
    Neurobiol Aging. 2004 Jan;25(1):105-10 PMID: 14675736
  215. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease.
    Hum Mol Genet. 2011 Dec 1;20(23):4515-29 PMID: 21873260
  216. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease.
    Arch Neurol. 2011 Jan;68(1):45-50 PMID: 20837824
  217. Mitochondrial fusion and fission in mammals.
    Annu Rev Cell Dev Biol. 2006;22:79-99 PMID: 16704336
  218. Elevated levels of fragmented DNA nucleosomes in native and activated lymphocytes indicate an enhanced sensitivity to apoptosis in sporadic Alzheimer's disease. Specific differences to vascular dementia.
    Dement Geriatr Cogn Disord. 2001 Mar-Apr;12(2):98-105 PMID: 11173881
  219. Elevated levels of the Kearns-Sayre syndrome mitochondrial DNA deletion in temporal cortex of Alzheimer's patients.
    Mutat Res. 1997 Oct 6;379(2):253-62 PMID: 9357554
  220. Apoptosis and Alzheimer's disease.
    J Neural Transm (Vienna). 2000;107(11):1325-44 PMID: 11145007
  221. Nitric oxide links mitochondrial fission to Alzheimer's disease.
    Sci Signal. 2009 May 05;2(69):pe29 PMID: 19417214
  222. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease.
    FASEB J. 2004 Feb;18(2):323-5 PMID: 14656990
  223. Neuronal protection by sirtuins in Alzheimer's disease.
    J Neurochem. 2006 Jan;96(2):305-13 PMID: 16219030
  224. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease.
    Neurobiol Aging. 2003 Nov;24(7):915-9 PMID: 12928050
  225. Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers.
    Eur J Pharmacol. 2007 May 7;562(1-2):20-7 PMID: 17336290
  226. The machines that divide and fuse mitochondria.
    Annu Rev Biochem. 2007;76:751-80 PMID: 17362197
  227. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains.
    Genomics. 1994 Sep 15;23(2):471-6 PMID: 7835898
  228. Alzheimer disease: caspases first.
    Nat Rev Neurol. 2010 Nov;6(11):587-8 PMID: 21048797
  229. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.
    Lancet Neurol. 2007 Dec;6(12):1045-53 PMID: 17980667
  230. Mitochondrial alterations in Alzheimer's disease.
    J Alzheimers Dis. 2006 Jul;9(2):119-26 PMID: 16873959
  231. Near-infrared spectroscopy of blood plasma for diagnosis of sporadic Alzheimer's disease.
    J Alzheimers Dis. 2009;17(2):391-7 PMID: 19363272
  232. Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport.
    J Neurosci. 2003 Jun 1;23(11):4499-508 PMID: 12805290
  233. A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer's disease.
    J Alzheimers Dis. 2010;20 Suppl 2:S401-12 PMID: 20463393
  234. Mitochondria as a therapeutic target in Alzheimer's disease and diabetes.
    CNS Neurol Disord Drug Targets. 2009 Dec;8(6):492-511 PMID: 19702564
  235. Abnormal mitochondrial dynamics--a novel therapeutic target for Alzheimer's disease?
    Mol Neurobiol. 2010 Jun;41(2-3):87-96 PMID: 20101529
  236. Tau neurofibrillary pathology and microtubule stability.
    J Mol Neurosci. 2002 Dec;19(3):289-93 PMID: 12540054
  237. Free radicals as mediators of neuronal injury.
    Cell Mol Neurobiol. 1998 Dec;18(6):667-82 PMID: 9876873
  238. Mitochondria are related to synaptic pathology in Alzheimer's disease.
    Int J Alzheimers Dis. 2011;2011:305395 PMID: 21922047
  239. Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment.
    Arch Neurol. 2007 Jul;64(7):954-6 PMID: 17620484
  240. Microtubules facilitate autophagosome formation and fusion of autophagosomes with endosomes.
    Traffic. 2006 Feb;7(2):129-45 PMID: 16420522
  241. Treating neurodegeneration by modifying mitochondria: potential solutions to a "complex" problem.
    Antioxid Redox Signal. 2007 Oct;9(10):1591-603 PMID: 17663643
  242. Amyloid deposition as the central event in the aetiology of Alzheimer's disease.
    Trends Pharmacol Sci. 1991 Oct;12(10):383-8 PMID: 1763432
  243. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).
    CNS Drug Rev. 2005 Winter;11(4):353-68 PMID: 16614735
  244. Idebenone in senile dementia of Alzheimer type: a multicentre study.
    Arch Gerontol Geriatr. 1992 Nov-Dec;15(3):249-60 PMID: 15374364
  245. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease.
    Brain Res Mol Brain Res. 1994 Jul;24(1-4):336-40 PMID: 7968373
  246. Structural brain changes in normal individuals with a maternal history of Alzheimer's.
    Neurobiol Aging. 2011 Dec;32(12):2325.e17-26 PMID: 21316814
  247. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease.
    Neuropsychobiology. 1997;36(2):73-82 PMID: 9267856
  248. Cytoplasmic dynein regulates the subcellular distribution of mitochondria by controlling the recruitment of the fission factor dynamin-related protein-1.
    J Cell Sci. 2004 Sep 1;117(Pt 19):4389-400 PMID: 15304525
  249. Microtubule destruction induces tau liberation and its subsequent phosphorylation.
    FEBS Lett. 2010 Jul 16;584(14):3227-32 PMID: 20561519
  250. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ.
    Acta Neuropathol. 1995;89(1):35-41 PMID: 7709729
  251. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
    Curr Pharm Des. 2011;17(25):2603-12 PMID: 21728979
  252. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's.
    Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5949-54 PMID: 20231448
  253. Terminal dUTP nick end labeling (TUNEL) positive cells in the different regions of the brain in normal aging and Alzheimer patients.
    J Mol Neurosci. 1997 Apr;8(2):75-82 PMID: 9188038
  254. Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of oxygen and its one-electron reductants.
    Q Rev Biophys. 1996 May;29(2):169-202 PMID: 8870073
  255. DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay.
    J Neurosci. 1996 Mar 1;16(5):1710-9 PMID: 8774439
  256. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.
    J Pharmacol Exp Ther. 2008 Apr;325(1):146-53 PMID: 18199809
  257. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity.
    Nature. 1999 Apr 8;398(6727):513-7 PMID: 10206644
  258. Oxidative damage and mitochondrial decay in aging.
    Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10771-8 PMID: 7971961
  259. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons.
    EMBO J. 2006 Aug 23;25(16):3900-11 PMID: 16874299
  260. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
    Dement Geriatr Cogn Disord. 2010;30(2):131-46 PMID: 20733306
  261. Oxidative damage is the earliest event in Alzheimer disease.
    J Neuropathol Exp Neurol. 2001 Aug;60(8):759-67 PMID: 11487050
  262. Reactive oxygen species in cell responses to toxic agents.
    Hum Exp Toxicol. 2002 Feb;21(2):85-90 PMID: 12102502
  263. Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in the hippocampal formation.
    J Neuropathol Exp Neurol. 1993 Nov;52(6):580-5 PMID: 8229076
  264. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease.
    Nature. 1995 Jun 29;375(6534):754-60 PMID: 7596406
  265. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS.
    Science. 2005 Oct 14;310(5746):314-7 PMID: 16224023
  266. Mitochondrial generation of reactive oxygen species and its role in aerobic life.
    Curr Med Chem. 2003 Dec;10(23):2495-505 PMID: 14529465
  267. Impaired mitochondrial transport and Parkin-independent degeneration of respiratory chain-deficient dopamine neurons in vivo.
    Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12937-42 PMID: 21768369
  268. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease.
    Arch Neurol. 2002 May;59(5):794-8 PMID: 12020262
  269. Mechanisms of exercise-induced mitochondrial biogenesis in skeletal muscle.
    Appl Physiol Nutr Metab. 2009 Jun;34(3):465-72 PMID: 19448716
  270. Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?
    Neurobiol Aging. 2007 Oct;28(10):1465-80 PMID: 16876913
  271. A systematic SAR study of C10 modified paclitaxel analogues using a combinatorial approach.
    Comb Chem High Throughput Screen. 2002 Feb;5(1):39-48 PMID: 11860338
  272. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease.
    Neurosci Lett. 2010 Jan 18;469(1):6-10 PMID: 19914330
  273. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.
    Lancet. 2008 Jul 19;372(9634):216-23 PMID: 18640458
  274. Mitochondrial abnormalities in cortical dendrites from patients with Alzheimer's disease.
    J Submicrosc Cytol. 1985 Jul;17(3):459-64 PMID: 2991550
  275. Brain aging, Alzheimer's disease, and mitochondria.
    Biochim Biophys Acta. 2011 Dec;1812(12):1630-9 PMID: 21920438
  276. Oxidative metabolism in cultured fibroblasts derived from sporadic Alzheimer's disease (AD) patients.
    Neurosci Lett. 1997 Oct 24;236(1):13-6 PMID: 9404940
  277. Mitochondria-derived oxidative stress induces a heat shock protein response.
    J Neurosci Res. 2004 Nov 1;78(3):420-9 PMID: 15389841
  278. Apoptosis in Alzheimer's disease--an update.
    Apoptosis. 2000 Feb;5(1):9-16 PMID: 11227497
  279. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
    Alzheimers Dement. 2011 May;7(3):280-92 PMID: 21514248
  280. Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content.
    Hum Mol Genet. 2007 Nov 15;16(22):2720-2728 PMID: 17725983
  281. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons.
    Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4441-6 PMID: 18332434
  282. The axonal transport of mitochondria.
    J Cell Sci. 2005 Dec 1;118(Pt 23):5411-9 PMID: 16306220
  283. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage.
    J Mol Neurosci. 2007;31(2):165-70 PMID: 17478890
  284. Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis.
    J Neural Transm Suppl. 2007;(72):189-93 PMID: 17982894
  285. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins.
    J Neurochem. 1997 Sep;69(3):1161-9 PMID: 9282939
  286. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo.
    FASEB J. 1998 Dec;12(15):1777-83 PMID: 9837868
  287. Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology.
    J Neuropathol Exp Neurol. 1997 Jan;56(1):86-93 PMID: 8990132
  288. Editorial: The prevalence and malignancy of Alzheimer disease. A major killer.
    Arch Neurol. 1976 Apr;33(4):217-8 PMID: 1259639
Article Info
Journal
Advances in pharmacology (San Diego, Calif.)
Abbr.
Adv Pharmacol
ISSN
1557-8925
DOI
10.1016/B978-0-12-394816-8.00003-9
Published
2012-00-00
Pages
83-126
Language
English
Region
United States
NLM ID
9015397
PMCID
PMC3625400
Subset
IM
Grants
NIA NIH HHS · P30 AG035982 · United States
NIA NIH HHS · P30AG035982 · United States
External Links
PubMed source DOI: 10.1016/B978-0-12-394816-8.00003-9 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2